Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) - Important safety information from Genzyme as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 25/06/2009


Problem Or Issue:

Important Safety Information communication from Genzyme on the shortage of Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta), which are used to treat patients with Gaucher disease and Fabry disease, respectively.

Important Safety Information - Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta)


« Back